Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) have received an average rating of “Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued a report on the stock in the last year is $15.00.
A number of brokerages have issued reports on TNYA. William Blair began coverage on shares of Tenaya Therapeutics in a research note on Monday, June 10th. They set an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a research note on Monday, July 8th. Finally, Canaccord Genuity Group cut their price objective on shares of Tenaya Therapeutics from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, May 16th.
Read Our Latest Research Report on TNYA
Institutional Trading of Tenaya Therapeutics
Tenaya Therapeutics Trading Down 2.8 %
Shares of Tenaya Therapeutics stock opened at $3.88 on Monday. Tenaya Therapeutics has a 12-month low of $1.66 and a 12-month high of $7.01. The firm has a market capitalization of $304.65 million, a price-to-earnings ratio of -2.37 and a beta of 2.42. The firm’s 50 day simple moving average is $3.57 and its two-hundred day simple moving average is $4.35.
Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. On average, sell-side analysts predict that Tenaya Therapeutics will post -1.59 EPS for the current fiscal year.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
Recommended Stories
- Five stocks we like better than Tenaya Therapeutics
- How to Calculate Inflation Rate
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Do ETFs Pay Dividends? What You Need to Know
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Investing in the High PE Growth Stocks
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.